Skip to Content
The pharma giant had a banner year in 2019, climbing 29 slots on the Global 500. Revenue rose almost 11%, to $46.8 billion, while profits leaped 58%, to $9.8 billion. Blockbuster cancer drug Keytruda, as well as an expanded line of animal medicines, have helped power Merck’s growth—though its share price has not seen as much of a lift as some competitors'. In the race to find a vaccine for COVID-19, Merck has adopted a slow pace compared to others in the industry. Rather than tout the company’s progress, CEO Kenneth Frazier has instead criticized industry “hype” and has warned that the process for developing an effective vaccine could take years
Lists ranking Merck
World’s Most Admired Companies - 2021After a year in which humanity leaned more heavily...READ MOREview in list
Change the World - 2020As we face unprecedented collective challenges, co...READ MOREview in list
Global 500 - 2020This year's Global 500 generated $33.3 trillion in...READ MOREview in list
Fortune 500 - 2020This year's Fortune 500 marks the 66th running of ...READ MOREview in list